Goldman Sachs Affirms Buy Rating for JD Health, Sets Price Target at HK$65

Deep News

07/21

Investment bank Goldman Sachs has issued a research report, stating that JD HEALTH's (06618) second-quarter revenue growth is anticipated to broadly align with market expectations. While the performance of the 618 shopping festival was relatively subdued, driven by sustained market share gains in its core product categories, the current forecast projects a year-on-year revenue increase of 18% for the second quarter.

Goldman Sachs currently forecasts that JD HEALTH's adjusted operating profit margin for the second quarter will be 7.1%, indicating continued improvement compared to the same period last year. The firm also anticipates an acceleration in the company's growth during the second half of the year. Consequently, Goldman Sachs has maintained its "Buy" rating on the stock, with a target price set at HK$65.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1144611319"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1144611319\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1144611319?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-21 23:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144611319","market":"nz","top_or_hot":-1,"title":"Goldman Sachs Affirms Buy Rating for JD Health, Sets Price Target at HK$65","media":"Deep News","content":"<p>Investment bank Goldman Sachs has issued a research report, stating that <b>JD HEALTH</b>'s (<b>06618</b>) second-quarter revenue growth is anticipated to broadly align with market expectations. While the performance of the 618 shopping festival was relatively subdued, driven by sustained market share gains in its core product categories, the current forecast projects a year-on-year revenue increase of 18% for the second quarter.<br><br>Goldman Sachs currently forecasts that <b>JD HEALTH</b>'s adjusted operating profit margin for the second quarter will be 7.1%, indicating continued improvement compared to the same period last year. The firm also anticipates an acceleration in the company's growth during the second half of the year. Consequently, Goldman Sachs has maintained its \"Buy\" rating on the stock, with a target price set at HK$65.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Goldman Sachs Affirms Buy Rating for JD Health, Sets Price Target at HK$65</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGoldman Sachs Affirms Buy Rating for JD Health, Sets Price Target at HK$65\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time smaller\">2026-07-21 23:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Investment bank Goldman Sachs has issued a research report, stating that <b>JD HEALTH</b>'s (<b>06618</b>) second-quarter revenue growth is anticipated to broadly align with market expectations. While the performance of the 618 shopping festival was relatively subdued, driven by sustained market share gains in its core product categories, the current forecast projects a year-on-year revenue increase of 18% for the second quarter.<br><br>Goldman Sachs currently forecasts that <b>JD HEALTH</b>'s adjusted operating profit margin for the second quarter will be 7.1%, indicating continued improvement compared to the same period last year. The firm also anticipates an acceleration in the company's growth during the second half of the year. Consequently, Goldman Sachs has maintained its \"Buy\" rating on the stock, with a target price set at HK$65.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"","article_id":"1144611319","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144611319","pubTimestamp":1784646085,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Investment bank Goldman Sachs has issued a research report, stating that JD HEALTH's (06618) second-quarter revenue growth is anticipated to broadly align with market expectations. While the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"86618":"京东健康-R","BK1583":"高瓴概念","EWH":"香港ETF-iShares MSCI","SGXZ62798434.SGD":"MAYBANK ASIAN GROWTH AND INCOME-I \"A\" (SGDHDG) ACC","06618":"京东健康","BK1571":"互联网医疗","BK1615":"港股-互联网","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","BK1589":"北水核心资产","BK1515":"抗疫概念","BK1247":"药品零售","BK1142":"互联网与直销零售","SGXZ86797644.SGD":"MAYBANK ASIAN GROWTH AND INCOME-I \"A\" (SGDHDG) INC","BK1591":"就地过年概念","LU0051755006.USD":"摩根大通中国A (dist)"},"translate_title":"高盛确认京东健康买入评级，目标价65港元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"86618":1,"EWH":1,"06618":1},"content_text":"Investment bank Goldman Sachs has issued a research report, stating that JD HEALTH's (06618) second-quarter revenue growth is anticipated to broadly align with market expectations. While the performance of the 618 shopping festival was relatively subdued, driven by sustained market share gains in its core product categories, the current forecast projects a year-on-year revenue increase of 18% for the second quarter.Goldman Sachs currently forecasts that JD HEALTH's adjusted operating profit margin for the second quarter will be 7.1%, indicating continued improvement compared to the same period last year. The firm also anticipates an acceleration in the company's growth during the second half of the year. Consequently, Goldman Sachs has maintained its \"Buy\" rating on the stock, with a target price set at HK$65.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}